A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors
Subjects must meet all of the following criteria to be eligible to participate in this
1. Willing and able to comply with the protocol and provide written informed consent.
2. Age greater than or equal to 18 years.
3. Histologically and/or cytologically confirmed metastatic melanoma which has
progressed after treatment with approved therapies or for which there are no standard
effective therapies available. CNS metastases from a primary melanoma are allowed.
4. Subjects must have melanoma tumor status established by a BRAF-gene analysis report
from a CLIA qualified laboratory.
5. Subjects must have at least one tumor lesion accessible to biopsy in addition to one
which is accurately and serially measurable according to RECIST 1.0 using either
CT/MRI or photography (as appropriate), and which measures > 1.5 cm in the longest
diameter for a non-lymph node and > 2.0 cm in the short axis diameter for a lymph
6. Female subjects of childbearing potential must agree to use medically acceptable
methods of contraception, such as abstinence, double-barrier method (e.g., condom and
spermicide; condom, diaphragm, and spermicide), intrauterine device (IUD), or have a
vasectomised partner. Female subjects who use hormonal contraceptives must also use
an additional approved method of contraception (as described previously).
Contraceptive measures must start either prior to or at Screening and continue
throughout the entire study period and for 2 months after the last dose drug is
administered. Pregnant and/or lactating females are excluded.
7. Male subjects must agree to use contraceptive methods such as abstinence, or
double-barrier method (e.g., condom and spermicide; condom, diaphragm, and
spermicide). Contraceptive measures must start either prior to or at Screening and
continue throughout the entire study period and for 2 months after the last dose of
study drug is administered.
8. Adequate bone marrow function defined as:
- Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
- Hemoglobin greater than or equal to 9.0 g/dL; however, a hemoglobin value < 9.0
g/dL is acceptable if it is corrected to greater than or equal to 9.0 g/dL by
growth factor or transfusion before the start of treatment
- Platelet count greater than or equal to 100 x 10^9/L.
9. Adequate renal function defined as:
- Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >50 mL/minute
per the Cockcroft-Gault formula 10 Adequate liver function defined as:
- Total Bilirubin within normal limits
- Alkaline phosphatase (AP), alanine transaminase (ALT), and aspartate
transaminase (AST) less than or equal to 2.5 x upper limit of normal (ULN)
- AP, ALT, and AST less than or equal to 5 x ULN in the case of liver metastases
and liver-specific AP less than or equal to 3 x ULN in the case of bone
metastases 11 Eastern Cooperative Oncology Group (ECOG) performance status less
than or equal to 1.
12. Life expectancy > 3 months.
Subjects who meet any of the following criteria are not eligible to participate in this
1. Known human immunodeficiency virus (HIV), clinical evidence of active viral hepatitis
B or C, or severe/uncontrolled infections or intercurrent illness that is unrelated
to the tumor.
2. Prior surgery, radiotherapy, chemotherapy, biologic therapy, or investigational
agents within 4 weeks prior to the first infusion and prior immunotherapy, hormonal,
or molecular-targeted therapy within 2 weeks prior to the first infusion. All acute
toxicities related to prior treatments should have resolved.
3. Active malignancy other than the present diagnosis within the past 24 months (except
treated non-melanoma skin cancer or carcinoma in situ of the cervix).
4. QT interval corrected for rate (QTc) > 450 msec on the electrocardiogram (ECG)
obtained at Screening (Day -21 to 0) using the Fridericia method for QTc analysis.
5. History or substance or alcohol abuse which, in the opinion of the investigator,
would prohibit participation in the study.
6. History of clinically significant cardiac impairment, congestive heart failure >New
York Heart Association (NYHA) cardiac disease classification Class II, unstable
angina, or myocardial infarction during the previous 6 months, or serious cardiac
7. Current significant co-morbid disease which, in the opinion of the investigator,
would exclude the subject from the study.